An Efficacy and Safety Study w/ Azstarys® in Children 4-12 Years of Age With ADHD (KP415P01)
A Multicenter, Dose-Optimized, Randomized, Double Blind, Efficacy and Safety Study With Azstarys® in Children 4 to 12 Years of Age With Attention Deficit/Hyperactivity Disorder
Sponsor: Almac
This PHASE4 trial investigates Attention Deficit/Hyperactivity Disorder and is currently completed. Almac leads this study, which shows 10 recorded versions since 2023 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
10 versions recorded-
Dec 2025 — Present [monthly]
Completed PHASE4
-
Jun 2025 — Dec 2025 [monthly]
Completed PHASE4
-
Sep 2024 — Jun 2025 [monthly]
Completed PHASE4
-
Aug 2024 — Sep 2024 [monthly]
Completed PHASE4
Status: Active Not Recruiting → Completed
-
Jul 2024 — Aug 2024 [monthly]
Active Not Recruiting PHASE4
▶ Show 5 earlier versions
-
May 2024 — Jul 2024 [monthly]
Active Not Recruiting PHASE4
Status: Recruiting → Active Not Recruiting
-
Feb 2024 — May 2024 [monthly]
Recruiting PHASE4
-
Jun 2023 — Feb 2024 [monthly]
Recruiting PHASE4
-
Mar 2023 — Jun 2023 [monthly]
Recruiting PHASE4
Status: Not Yet Recruiting → Recruiting
-
Feb 2023 — Mar 2023 [monthly]
Not Yet Recruiting PHASE4
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Almac
- Corium, Inc.
- Premier Research
- Prometrika, LLC
For direct contact, visit the study record on ClinicalTrials.gov .